Hero

Press Releases

Press Releases

Royalty Pharma Raises Full Year 2023 Guidance

NEW YORK, NY, March 15, 2023 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it has received a $475 million accelerated milestone payment from Pfizer, following the U.S. Food and Drug Administration (FDA) approval of Zavzpret (zavegepant)

Royalty Pharma Appoints Ashwin Pai as Executive Vice President, Investments

NEW YORK, NY, March 1, 2023 – Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Ashwin Pai, M.D. as Executive Vice President, Investments. Ashwin will join Royalty Pharma in April 2023, and will report to Chris Hite, Executive Vice President and Vice Chairman.

Royalty Pharma Reports Q4 and Full Year 2022 Results

NEW YORK, NY, February 15, 2023 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year 2022 and introduced full year 2023 guidance for Adjusted Cash Receipts(1) (non-GAAP financial measure).

Royalty Pharma to Present at Upcoming Investor Conferences

NEW YORK , NY,  February 09, 2023 - Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the months of February and March: SVB Securities Global Biopharma Conference on Thursday, February 16 at 10:40 a.m.

Royalty Pharma to Announce Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023

NEW YORK, NY, January 18, 2023 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2022 financial results on Wednesday, February 15, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at

Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J.P. Morgan Healthcare Conference

NEW YORK, NY, January 9, 2023 - Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments and the full year 2022 outlook

Royalty Pharma and Ionis Enter into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness

NEW YORK, NY, and CARLSBAD, CA, January 9, 2023 - Royalty Pharma plc (Nasdaq: RPRX) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Royalty Pharma has acquired an interest in Ionis’ royalty in Biogen’s SPINRAZA®

Royalty Pharma Announces Dividend Increase

NEW YORK, NY, January 9, 2023 - Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2023 of $0.20 per Class A share, reflecting a 5.3% increase in the company’s quarterly dividend over the previous quarter’s dividend.

Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 9

NEW YORK, NY, January 4, 2023 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 11:15 a.m. ET / 8:15 a.m. PT. 

Royalty Pharma Announces Expansion of Senior Leadership Team

NEW YORK, NY, December 15, 2022 - Royalty Pharma plc (Nasdaq: RPRX) today announced the expansion of its senior leadership team . This expansion highlights Royalty Pharma’s success in developing a talented, diverse and experienced
Displaying 1 - 10 of 115